Effect of Acute and Chronic Administration of l-Tyrosine on Nerve Growth Factor Levels in Rat Brain
Tóm tắt
Most inborn errors of tyrosine catabolism produce hypertyrosinemia. Neurological manifestations are variable and some patients are developmentally normal, while others show different degrees of developmental retardation. Considering that current data do not eliminate the possibility that elevated levels of tyrosine and/or its derivatives may have noxious effects on central nervous system development in some patients, the present study evaluated nerve growth factor (NGF) levels in hippocampus, striatum and posterior cortex of young rats. In our acute protocol, Wistar rats (10 and 30 days old) were killed 1 h after a single intraperitoneal administration of l-tyrosine (500 mg/kg) or saline. Chronic administration consisted of l-tyrosine (500 mg/kg) or saline injections 12 h apart for 24 days in Wistar rats (7 days old); the rats were killed 12 h after the last injection. NGF levels were then evaluated. Our findings showed that acute administration of l-tyrosine decreased NGF levels in striatum of 10-day-old rats. In the 30-day-old rats, NGF levels were decreased in hippocampus and posterior cortex. On the other hand, chronic administration of l-tyrosine increased NGF levels in posterior cortex. Decreased NGF may impair growth, differentiation, survival and maintenance of neurons.
Tài liệu tham khảo
Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1977–1982
Held PK (2006) Disorders of tyrosine catabolism. Mol Genet Metab 88:103–106
Paige DG, Clayton P, Bowron A, Harper JL (1992) Richner–Hanhart syndrome (oculocutaneous tyrosinaemia, tyrosinaemia type II). J R Soc Med 85:759–760
Chakrapani A, Holme E (2006) Disorders of tyrosine metabolism. In: Fernandes J, Saudubray JM, Van den Berghe G, Walter JM (eds) Inborn metabolic diseases. diagnosis and treatment, 4th edn. Springer, Würzburg, pp 233–243
Madan V, Gupta U (2006) Tyrosinaemia type II with diffuse plantar keratoderma and self-mutilation. Clin Exp Dermatol 31:54–56
Valikhani M, Akhyani M, Jafari AK, Barzegari M, Toosi S (2006) Oculocutaneous tyrosinaemia or tyrosinaemia type 2: a case report. J Eur Acad Dermatol Venereol 20:591–594
Pasternack SM, Betz RC, Brandrup F (2009) Identification of two new mutations in the TAT gene in a Danish family with tyrosinaemia type II. Br J Dermatol 160:704–706
Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237:154–1162
Friedman WJ, Greene LA (1999) Neurotrophin signaling via Trks and p75. Exp Cell Res 253:131–142
Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381–391
Micera A, Lambiase A, Puxeddu I, Aloe L, Stampachiacchiere B, Levi-Evischaffer F, Bonini S, Bonini S (2006) Nerve growth factor effect on human primary fibroblastic-keratocytes: possible mechanism during corneal healing. Exp Eye Res 83:747–757
García-Cazola A, Wolf IN, Serrano M, Moog U, Perez-Dueñas B, Póo P, Pineda M, Campistol J, Hoffmann GF (2009) Mental retardion and inborn errors of metabolism. J Inherit Metab Dis 32:599–608
Morre MC, Hefti F, Wurtman RJ (1980) Regional tyrosine levels in rat brain after tyrosine administration. J Neural Transm 49:45–50
Bongiovanni R, Yamamoto BK, Simpson C, Jaskiw GE (2003) Pharmacokinetics of systemically administered tyrosine: a comparison of serum, brain tissue and in vivo microdialysate levels in the rat. J Neurochem 87:310–317
Lowry OH, Rosebough NG, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Cohen S, Levimontalcini R, Hamburger VA (1954) Nerve growth stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA 40:1014–1018
Thoenen H, Barde YA (2006) Physiology of nerve growth factor. Physiol Rev 60:1133–1284
Konkol RJ, Mailman RB, Bendeich EG, Garrison AM, Mueller RA, Breese GR (1978) Evaluation of the effects of nerve growth factor and anti-nerve growth factor on the development of central catecholamine-containing neurons. Brain Res Bull 144:277–285
Schwab ME, Otten U, Agid Y, Thoenen H (1979) Nerve growth factor (NGF) in the rat CNS: absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra. Brain Res Bull 168:473–483
Olson L, Ebendal T, Seiger A (1979) NGF and anti-NGF: evidence against effects on fiber growth in locus coeruleus from cultures of perinatal CNS tissues. Dev Neurosci 2:160–176
Dreyfus CF, Peterson ER, Crain SM (1980) Failure of nerve growth factor to affect fetal mouse brain stem catecholaminergic neurons in culture. Brain Res Bull 194:540–547
Seiler M, Schwab ME (1984) Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Res Bull 300:33–39
Hellweg R, Nitsh R, Hock C, Jaksch M, Hoyer S (1992) Nerve growth factor and choline acetyltransferase activity level the rat following experimental impairment cerebral glucose and energy metabolism. J Neurosci Res 31:479–486
Loy R, Moore RY (1977) Anomalous innervation of the hippocampal formation by peripheral sympathetic axons following mechanical injury. Exp Neurol 57:645–650
Korsching S, Auburger G, Heumann R, Scott J, Thoenen H (1985) Levels of nerve growth factor and it is mRNA in the central nervous system of the rat with cholinergicinnervation. EMBO J 4:1389–1393
Ferreira GK, Carvalho-Silva M, Gonçalves CL, Vieira JS, Scaini G, Ghedim FV, Deroza PF, Zugno AI, Pereira TC, Oliveira GM, Kist LW, Bogo MR, Schuck PF, Ferreira GC, Streck EL (2012) l-Tyrosine administration increases acetylcholinesterase activity in rats. Neurochem Internat 61:1370–1374
Zhang L, Jope RS (1999) Oxidative stress differentially modulates phosphorylation of ERK, p38 and CREB induced by NGF or EGF in PC12 cells. Neurobiol Aging 20:271–278
Sgaravatti AM, Magnusson AS, de Oliveira AS, Rosa AP, Mescka CP, Zanin FR, Pederzolli CD, Wyse AT, Wannmacher CM, Wajner M, Dutra-Filho CS (2009) Tyrosine administration decreases glutathione and stimulates lipid and protein oxidation in rat cerebral cortex. Metab Brain Dis 24:415–425
Kitamura N, Konno A, Kuwahara T, Komagiri Y (2005) Nerve growth factor-induced hyperexcitability of rat sensory neuron in culture. Biomed Res 26:123–130
Hawkins RA, Mans AK, Biebuyck JF (1982) Amino acid supply to individual cerebral structures in awake and anesthetized rats. Am J Physiol 242:E1–E11
Miller LP, Pardridge WM, Braun LD, Oldendorf WH (1985) Kinetic constants for blood–brain barrier amino acid transport in conscious rats. J Neurochem 45:427–1432
Colombo JP, Bachmann C, Cervantes H, Kokorovic M, Perritaz R (1996) Tyrosine uptake and regional brain monoamine metabolites in a rat model resembling congenital hyperammonemia. Pediatr Res 39:1036–1040
Reichel A, Begley DJ, Ermisch A (1996) Arginine vasopressin reduces the blood-brain transfer of 1-tyrosine and 1-valine: further evidence of the effect of the peptide on the 1-system transporter at the blood–brain barrier. Brain Res Bull 713:232–239
Morgane PJ, Austin-LaFrance RJ, Bronzino JD, Tonkiss J, Galler JR (1992) Malnutrition and the developing central nervous system. In: Isaacson RL, Jensen KF (eds) The vulnerable brain: nutrition and toxins. Plenum Publishing Corporation, New York, pp 3–44
Uylings HB (2000) Development of the cerebral cortex in rodents and man. Eur J Morphol 38:309–312